A French study which includes 17,664 patients, identified 0.93% of non-squamous NSCLC with multiple genetic alterations involving oncogenic drivers, and the frequent concomitant mutations associated with KRAS included EGFR (15%) mutations [28]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.